Screener
Viking Therapeutics VKTX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(158,325) | $(45,629) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of investment premiums | (1,293) | (3,133) |
| Amortization of financing costs | — | 24 |
| Stock-based compensation | 10,337 | 11,348 |
| Amortization of right-of-use assets | 85 | 111 |
| Interest expense related to operating lease liability | 1 | 10 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Viking Therapeutics (VKTX) reported accretion (amortization) of discounts and premiums, investments of $1.29M in Q1 2026.
- How has Viking Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Viking Therapeutics's accretion (amortization) of discounts and premiums, investments decreased by 58.7% year-over-year, from $3.13M to $1.29M.
- What is the long-term trend for Viking Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Viking Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 24.2% compound annual growth rate (CAGR), from -$3.91M to $9.28M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income for the amortization of premiums or accretion of discounts on investment securities held by the company. It reflects the gradual adjustment of the carrying value of debt securities toward their face value over time. This metric is essential for reconciling net income to cash flow from operations by removing non-cash interest-related accounting entries.
Ask your AI about Viking Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude